Neostem (NBS +5.7%) gets a boost from an upgrade at Aegis Capital with a Buy rating and a $2.50...

|By:, SA News Editor

Neostem (NBS +5.7%) gets a boost from an upgrade at Aegis Capital with a Buy rating and a $2.50 price target. Aegis says NBS represents a unique participant in the stem cell sector, given the fact that it has four different technology platforms and a solid lead product candidate, AMR-001, which is a stem cell-based therapeutic for cardiovascular disease with tremendous potential. The drug is currently in a proof-of-concept Phase 2 trial that is slated to report data early next year, and positive results could land it a partnership with Baxter (BAX).